Brokerages Set Teladoc Health, Inc. (NYSE:TDOC) Target Price at $11.81

Shares of Teladoc Health, Inc. (NYSE:TDOC) have earned a consensus rating of “Hold” from the twenty research firms that are covering the stock, Marketbeat reports. Fourteen analysts have rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $11.81.

Several equities research analysts have recently weighed in on TDOC shares. Royal Bank of Canada upped their price objective on Teladoc Health from $9.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, October 9th. Stifel Nicolaus lowered their price target on Teladoc Health from $16.00 to $9.00 and set a “hold” rating on the stock in a research report on Thursday, August 1st. JPMorgan Chase & Co. cut their price objective on Teladoc Health from $16.00 to $9.00 and set a “neutral” rating for the company in a report on Monday, August 26th. DA Davidson lowered their target price on shares of Teladoc Health from $12.00 to $8.00 and set a “neutral” rating on the stock in a report on Thursday, August 1st. Finally, Evercore ISI lifted their price target on shares of Teladoc Health from $8.00 to $9.00 and gave the company an “in-line” rating in a report on Tuesday, October 8th.

Teladoc Health Stock Performance

Shares of NYSE TDOC opened at $9.30 on Friday. Teladoc Health has a one year low of $6.76 and a one year high of $22.54. The company has a current ratio of 1.66, a quick ratio of 1.62 and a debt-to-equity ratio of 0.66. The business has a fifty day simple moving average of $8.12 and a 200 day simple moving average of $10.01. The firm has a market capitalization of $1.58 billion, a price-to-earnings ratio of -6.60 and a beta of 0.91.

Teladoc Health (NYSE:TDOC) last announced its quarterly earnings data on Wednesday, July 31st. The health services provider reported ($0.28) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.08. Teladoc Health had a negative net margin of 38.54% and a negative return on equity of 10.25%. The company had revenue of $642.44 million during the quarter, compared to analysts’ expectations of $649.34 million. Sell-side analysts expect that Teladoc Health will post -1.18 EPS for the current year.

Insider Buying and Selling

In other Teladoc Health news, insider Vidya Raman-Tangella sold 3,857 shares of the firm’s stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $8.14, for a total value of $31,395.98. Following the transaction, the insider now directly owns 33,667 shares of the company’s stock, valued at approximately $274,049.38. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, insider Vidya Raman-Tangella sold 3,857 shares of the company’s stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $8.14, for a total value of $31,395.98. Following the completion of the sale, the insider now owns 33,667 shares in the company, valued at approximately $274,049.38. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CMO Stephany Verstraete sold 15,000 shares of the stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $7.60, for a total value of $114,000.00. Following the completion of the transaction, the chief marketing officer now directly owns 45,158 shares in the company, valued at $343,200.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 57,377 shares of company stock valued at $438,054 over the last ninety days. Insiders own 0.95% of the company’s stock.

Institutional Investors Weigh In On Teladoc Health

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in Teladoc Health by 11.8% during the 4th quarter. Vanguard Group Inc. now owns 17,515,127 shares of the health services provider’s stock worth $377,451,000 after buying an additional 1,855,480 shares during the period. Point72 Asset Management L.P. raised its holdings in shares of Teladoc Health by 221.9% during the second quarter. Point72 Asset Management L.P. now owns 5,303,123 shares of the health services provider’s stock worth $51,865,000 after acquiring an additional 3,655,436 shares during the period. Rubric Capital Management LP bought a new stake in Teladoc Health in the 2nd quarter valued at $45,267,000. Clearline Capital LP lifted its position in Teladoc Health by 395.6% in the 2nd quarter. Clearline Capital LP now owns 4,364,201 shares of the health services provider’s stock valued at $42,682,000 after acquiring an additional 3,483,665 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its stake in Teladoc Health by 1.7% in the 2nd quarter. Bank of New York Mellon Corp now owns 916,129 shares of the health services provider’s stock worth $8,960,000 after purchasing an additional 14,910 shares during the period. 76.82% of the stock is currently owned by institutional investors and hedge funds.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.